1. Arias-de la Torre J, Vilagut G, Ronaldson A, Serrano-Blanco A, Martín V, Peters M, et al. Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. Lancet Public Health. 2021;6:e729-38.

https://doi.org/10.1016/S2468-2667(21)00047-5

PMid:33961802 

2. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700-12.

PMid:34634250

3. Sempere Vedúa E, Salazar Fraileb J, Palop Larreac V, Vicens Caldenteyd C. Evolution of the use of antidepressants, anxiolytics and hypnotics in Valencia. Period 2000-2010. Aten Primaria. 2014;46:416-25.

https://doi.org/10.1016/j.aprim.2013.11.006

PMid:24559729 PMCid:PMC6983638

4. Alabaku O, Yang A, Tharmarajah S, Suda K, Vigod S, Tadrous M. Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries. PLoS One. 2023;18:e0284389.

https://doi.org/10.1371/journal.pone.0284389

PMid:37099524 PMCid:PMC10132527

5. Friedlander AH, Mahler ME. Major depressive disorder. Psychopathology, medical management and dental implications. J Am Dent Assoc. 2001;132:629-38.

https://doi.org/10.14219/jada.archive.2001.0240

PMid:11367967 

6. Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, et al. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266.

https://doi.org/10.1016/j.pnpbp.2021.110266

PMid:33549697 

7. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009 Sep;195(3):202-10. Erratum in: Br J Psychiatry. 2010;196:417.

https://doi.org/10.1192/bjp.bp.108.061960

PMid:19721108 

8. Cockburn N, Pradhan A, Taing MW, Kisely S, Ford PJ. Oral health impacts of medications used to treat mental illness. J Affect Disord. 2017;223:184-93.

https://doi.org/10.1016/j.jad.2017.07.037

PMid:28759866 

9. Plemons JM, Al-Hashimi I, Marek CL; American Dental Association Council on Scientific Affairs. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2014;145:867-73.

https://doi.org/10.14219/jada.2014.44

PMid:25082939 

10. Young JP, Coleman A, Lader MH. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. Br J Psychiatry. 1987;151:337-40.

https://doi.org/10.1192/bjp.151.3.337

PMid:3322468 

11. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry. 1985;46:32-7.

PMid:3882679

12. Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin Psychiatry. 1985;46:369-72.

PMid:3897204

13. Ontiveros Sánchez de la Barquera JA, Brandi F, Brunner E. Estudio doble-ciego sobre fluoxetina vs. amitriptilina en los síntomas depresivos y de ansiedad, y calidad de vida de los adultos con depresión mayor. Salud mental. 1998:58-63.

PMid:

14. Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A. Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. J Clin Pharm Ther. 2003;28:379-84.

https://doi.org/10.1046/j.0269-4727.2003.00505.x

PMid:14632962 

15. Hashemi S, Shirazi HG, Mohammadi A, Zadeh-Bagheri G, Noorian Kh, Malekzadeh M. Nortriptyline versus fluoxetine in the treatment of major depressive disorder: a six-month, double-blind clinical trial. Clin Pharmacol. 2012;4:1-6.

https://doi.org/10.2147/CPAA.S23831

PMid:22359466 PMCid:PMC3284259

16. Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatry. 1991;52:62-7.

PMid:2050651

17. Beasley CM Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry. 1993;5:199-207.

https://doi.org/10.3109/10401239309148983

PMid:8281243 

18. Byerley WF, Reimherr FW, Wood DR, Grosser BI. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol. 1988;8:112-5.

https://doi.org/10.1097/00004714-198804000-00005

PMid:3286684 

19. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry. 1985;46:26-31

PMid:3882677

20. Diaz A, Fouilloux C, Ortiz S. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients. Proc West Pharmacol Soc. 2002;45:154-5.

PMid:12434564

21. Bremner JD. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry. 1984;45:414-9.

PMid:6384203

22. Remick RA, Keller FD, Gibson RE, Carter D. A comparison between Fluoxetine and Doxepin in depressed patients. Curr Ther Res Clin Exp. 1989;46:842-8.

PMid:

23. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985;46:20-5.

PMid:3882676

24. Novotny V, Faltus F. Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study. Hum Psychopharmacol. 2002;17:299-303.

https://doi.org/10.1002/hup.411

PMid:12404675 

25. Schwartz JA, McDaniel JS. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety. 1999;9:70-4.

https://doi.org/10.1002/(SICI)1520-6394(1999)9:2<70::AID-DA4>3.0.CO;2-L

PMid:10207661

26. Bougerol T, Scotto JC, Patris M, Strub N, Lemming O, Petersen HEH. Citalopram and Fluoxetine in Major Depression Comparison of Two Clinical Trials in a Psychiatrist Setting and in General Practice. Clin. Drug Invest. 1997;14:77-89.

https://doi.org/10.2165/00044011-199714020-00001

PMid:

27. Patted URH, Hema NG, Ngaraj AKM. A prospective randomized comparative study of safety and efficacy of vilazodone and fluoxetine in depression. Curr Top Pharmacol. 2021;25:97-105.

https://doi.org/10.31300/CTP.25.2021.97-105

PMid:

28. Taner E, Demir EY, Cosar B. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial. Adv Ther. 2006;23:974-87.

https://doi.org/10.1007/BF02850218

PMid:17276965 

29. Sheehan DV, Nemeroff CB, Thase ME, Entsuah R; EPIC 016 Study Group. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. Int Clin Psychopharmacol. 2009;24:61-86.

https://doi.org/10.1097/YIC.0b013e32831980f2

PMid:19238088 

30. Diaz-Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin R, Basquedano G, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther. 1998;20:467-76.

https://doi.org/10.1016/S0149-2918(98)80056-8

PMid:9663362 

31. Zhou J, Wang X, Feng L, Xiao L, Yang R, Zhu X, et al. Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study. BMC Psychiatry. 2021;21:260.

https://doi.org/10.1186/s12888-021-03253-8

PMid:34011310 PMCid:PMC8135153

32. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006;14:361-70.

https://doi.org/10.1097/01.JGP.0000194645.70869.3b

PMid:16582045 

33. Ghosh R, Gupta R, Bhatia MS, Tripathi AK, Gupta LK. Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine. Asian J Psychiatr. 2015;18:37-41.

https://doi.org/10.1016/j.ajp.2015.10.006

PMid:26514447 

34. Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. J Clin Pharm Ther. 2005;30:133-8.

https://doi.org/10.1111/j.1365-2710.2004.00585.x

PMid:15811165 

35. Lapierre YD, Joffe R, McKenna K, Bland R, Kennedy S, Ingram P, et al. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci. 1997;22:118-26.

PMid:9074306

36. Lonnqvist J, Sintonen H, Syvälahti E, Appelberg B, Koskinen T, Mannikko T, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand. 1994;89:363-9.

https://doi.org/10.1111/j.1600-0447.1994.tb01530.x

PMid:8085464 

37. Lehert P, Poirier-Littre MF, Pringuey D, Galinowski A. New statistical proposals to evaluate the benefit/risk ratio of long-term treatment of depression: application to a one-year double-blind study comparing medifoxamine with fluoxetine. Clin Drug Investig. 1998;15:285-95.

https://doi.org/10.2165/00044011-199815040-00004

PMid:18370483 

38. Shu L, Sulaiman AH, Huang YS, Fones Soon Leng C, Crutel VS, Kim YS. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder. Asian J Psychiatr. 2014;8:26-32.

https://doi.org/10.1016/j.ajp.2013.09.009

PMid:24655622 

39. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry. 1998;59:217-24.

https://doi.org/10.4088/JCP.v59n0502

PMid:9632030 

40. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005;25:441-7.

https://doi.org/10.1097/01.jcp.0000178416.60426.29

PMid:16160619 

41. Bertram U, Kragh-Sørensen P, Rafaelsen OJ, Larsen NE. Saliva secretion following long-term antidepressant treatment with nortriptyline controlled by plasma levels. Acta Psychiatr Scand Suppl. 1981;290:357-63.

https://doi.org/10.1111/j.1600-0447.1981.tb00740.x

PMid:6939317 

42. Shein K, Smith SE. Structure-activity relationships for the anticholinoceptor action of tricyclic antidepressants. Br J Pharmacol. 1978;62:567-71.

https://doi.org/10.1111/j.1476-5381.1978.tb07763.x

PMid:656701 PMCid:PMC1668048

43. Moore PA, Guggenheimer J. Medication-induced hyposalivation: etiology, diagnosis, and treatment. Compend Contin Educ Dent. 2008;29:50-5.

PMid:18361341

44. Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol. 1995;40:983-9.

https://doi.org/10.1016/0003-9969(95)00079-5

PMid:8670028